JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer (2015) 1.39

Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med (2014) 1.11

NF-κB gene signature predicts prostate cancer progression. Cancer Res (2014) 1.09

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife (2013) 1.02

The 2 Faces of JNK Signaling in Cancer. Genes Cancer (2013) 1.00

PLZF mediates the PTEN/AKT/FOXO3a signaling in suppression of prostate tumorigenesis. PLoS One (2013) 0.88

PTEN modulators: a patent review. Expert Opin Ther Pat (2013) 0.88

Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. Am J Pathol (2012) 0.87

Prostate tumorigenesis induced by PTEN deletion involves estrogen receptor β repression. Cell Rep (2015) 0.85

β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1. J Cell Physiol (2013) 0.83

Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. Cancer Res (2014) 0.81

Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice. Arterioscler Thromb Vasc Biol (2016) 0.80

Loss of JUNB/AP-1 promotes invasive prostate cancer. Cell Death Differ (2014) 0.80

Extracellular signal-regulated kinase signaling regulates the opposing roles of JUN family transcription factors at ETS/AP-1 sites and in cell migration. Mol Cell Biol (2014) 0.79

Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis. Cancer Res (2015) 0.78

Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. J Biol Chem (2016) 0.78

Diversin is overexpressed in breast cancer and accelerates cell proliferation and invasion. PLoS One (2014) 0.77

Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in Caenorhabditis elegans. Aging Cell (2015) 0.77

Prostate cancer and the unfolded protein response. Oncotarget (2016) 0.77

JunB and PTEN in prostate cancer: 'loss is nothing else than change'. Cell Death Differ (2015) 0.76

n-3 Polyunsaturated Fatty Acids and their Role in Cancer Chemoprevention. Curr Pharmacol Rep (2015) 0.76

Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors. Am J Hum Genet (2016) 0.76

Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling. BMC Cancer (2014) 0.76

Correlating phosphoproteomic signaling with castration resistant prostate cancer survival through regression analysis. Mol Biosyst (2014) 0.75

Re: JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. J Urol (2013) 0.75

αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Res (2016) 0.75

Loss of flfl Triggers JNK-Dependent Cell Death in Drosophila. Biomed Res Int (2015) 0.75

miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth. Oncotarget (2017) 0.75

Alternative promotion and suppression of metastasis by JNK2 governed by its phosphorylation. Oncotarget (2017) 0.75

Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34

Signal transduction by the JNK group of MAP kinases. Cell (2000) 18.24

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science (2000) 8.56

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26

A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature (2009) 5.65

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57

Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43

Defective T cell differentiation in the absence of Jnk1. Science (1998) 4.40

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40

Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23

Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity (1998) 3.70

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res (1997) 3.55

Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34

Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33

Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells (2007) 2.50

Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res (2009) 2.49

MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev (2001) 2.48

The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47

Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43

JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell (2003) 2.39

JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev (1998) 2.29

Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26

Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10

The role of JNK in the development of hepatocellular carcinoma. Genes Dev (2011) 2.07

Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res (2001) 2.00

Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs. Sci Signal (2009) 1.97

JNK regulates autocrine expression of TGF-beta1. Mol Cell (2004) 1.81

Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene (2007) 1.79

Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res (2002) 1.77

Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A (2007) 1.67

Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer (1994) 1.64

Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet (2002) 1.48

Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res (1999) 1.43

MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One (2011) 1.38

Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res (2002) 1.33

Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33

Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest (1997) 1.32

Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS One (2009) 1.24

Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res (2001) 1.18

Role of JNK in mammary gland development and breast cancer. Cancer Res (2011) 1.14

Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol (2011) 1.12

Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model. PLoS One (2010) 1.12

Targeted deletion of the mitogen-activated protein kinase kinase 4 gene in the nervous system causes severe brain developmental defects and premature death. Mol Cell Biol (2007) 1.11

Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab Invest (2002) 1.11

Role of JNK in a Trp53-dependent mouse model of breast cancer. PLoS One (2010) 1.05

Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol (2007) 0.99

Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev (1999) 0.92

New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett (2008) 0.90

Mitogen-activated protein kinase kinase 4/c-Jun NH2-terminal kinase kinase 1 protein expression is subject to translational regulation in prostate cancer cell lines. Mol Cancer Res (2008) 0.90

Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents. Med Res Rev (2011) 0.89

Metastatic burden in nude mice organs measured using prostate tumor PC-3 cells expressing the luciferase gene as a quantifiable tumor cell marker. Prostate (2000) 0.85

The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11

Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42

Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86

Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83

Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science (2005) 11.31

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74

Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity (2006) 10.58

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76

NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell (2011) 9.75

Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol (2006) 9.53

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature (2008) 9.16

Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A (2004) 9.00

Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 8.83

Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11

The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04

MAP kinases in the immune response. Annu Rev Immunol (2001) 7.62

Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med (2004) 7.49

Interchromosomal associations between alternatively expressed loci. Nature (2005) 7.45

PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 7.35

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32

IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 6.79

Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63

T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity (2007) 6.61

Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature (2007) 6.58

Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science (2006) 6.55

Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52

Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38

A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20

Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00

The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity (2011) 6.00

HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 5.99

Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A (2005) 5.96

RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature (2002) 5.95

Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity (2006) 5.91

The JNK signal transduction pathway. Curr Opin Cell Biol (2007) 5.86

Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J (2003) 5.78

Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity (2007) 5.73

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59

The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A (2008) 5.59

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54

Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell (2004) 5.50

Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol (2003) 5.38

Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 5.32

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31

A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science (2008) 5.28

A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol (2009) 5.26

A toll-like receptor that prevents infection by uropathogenic bacteria. Science (2004) 5.26

Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. Science (2009) 5.24

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13

Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest (2009) 5.09

JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 5.01

Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96

Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med (2007) 4.95

Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A (2004) 4.88

TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science (2005) 4.86

RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85

The NLR gene family: a standard nomenclature. Immunity (2008) 4.77

A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2010) 4.75

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70

The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nat Immunol (2006) 4.70

Long-range intrachromosomal interactions in the T helper type 2 cytokine locus. Nat Immunol (2004) 4.67

Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63

TGF-beta: a master of all T cell trades. Cell (2008) 4.60

Transforming growth factor-beta in T-cell biology. Nat Rev Immunol (2002) 4.50

V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49

Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med (2007) 4.47

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44

Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol (2006) 4.44

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43

Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32

T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med (2005) 4.28

Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med (2006) 4.28

Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol (2003) 4.15

The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature (2002) 4.15

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12

PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07

Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity (2007) 4.07

Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03

Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity (2006) 4.02

Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02

Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99

Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A (2009) 3.99

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78